Regenxbio INC. (RGNX) — 8-K Filings

8-K Filings (11)

• REGENXBIO Inc. Files 8-K: Corporate Updates — Aug 18, 2025 Risk: low
  REGENXBIO Inc. filed an 8-K on August 18, 2025, reporting other events and financial statements. The filing details the company's principal executive offices lo
• REGENXBIO Inc. Files 8-K on Shareholder Matters — Jun 3, 2025 Risk: low
  REGENXBIO Inc. filed an 8-K on June 3, 2025, reporting on matters submitted to a vote of security holders as of May 30, 2025. The filing details the company's c
• REGENXBIO Inc. Files 8-K: Material Agreement and Financial Update — May 19, 2025 Risk: medium
  On May 16, 2025, REGENXBIO Inc. entered into a material definitive agreement, which also created a direct financial obligation for the company. The filing also
• REGENXBIO Inc. Files 8-K: Regulation FD Disclosure & Other Events — Mar 4, 2025 Risk: low
  On March 3, 2025, REGENXBIO Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements and ex
• REGENXBIO Inc. Files 8-K: Material Agreement — Jan 14, 2025 Risk: medium
  On January 14, 2025, REGENXBIO Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements/ex
• REGENXBIO Inc. Files 8-K Report — Dec 9, 2024 Risk: low
  On December 9, 2024, REGENXBIO Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material
• REGENXBIO Inc. Files 8-K: Officer/Director Changes & Compensation — Sep 17, 2024 Risk: medium
  REGENXBIO Inc. filed an 8-K on September 17, 2024, reporting events as of September 16, 2024. The filing pertains to the departure of directors or certain offic
• REGENXBIO Appoints New CSO, Dr. Gregory — Aug 6, 2024 Risk: medium
  REGENXBIO Inc. announced on August 1, 2024, the appointment of Dr. Philip J. Gregory as Chief Scientific Officer, effective August 5, 2024. Dr. Gregory will rec
• REGENXBIO Appoints New Chief Medical Officer — Jun 13, 2024 Risk: low
  On June 12, 2024, REGENXBIO Inc. announced the appointment of Dr. V. Michael Weiss as Chief Medical Officer, effective June 10, 2024. Dr. Weiss will receive an
• REGENXBIO Files 8-K on Shareholder Votes and Financials — Jun 3, 2024 Risk: low
  On May 31, 2024, REGENXBIO Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The filing inclu
• REGENXBIO Files 8-K: Other Events & Exhibits — Mar 11, 2024 Risk: medium
  REGENXBIO Inc. filed an 8-K on March 11, 2024, reporting an event that occurred on March 6, 2024. The filing pertains to 'Other Events' and 'Financial Statement

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX